Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T. H., Hochhaus, A., Hughes, T. P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,550

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H. M., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,516

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Kantarjian, H., Sawyers, C. L., Hochhaus, A., Guilhot, F., Schiffer, C. A., Gambacorti-Passerini, C. B., Niederwieser, D. W., Resta, D. J., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,005

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,614

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan‐Jacob, S. W., Ray, A., Huntly, B. J. P., Fabbro, D., Fendrich, G., Hall–Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,509

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

O’Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,296

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,274

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,201

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Hochhaus, A., Kreil, S., Corbin, A. S., Rosée, P. G. L., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N. C. P., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 920

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K. M., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 767

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Kantarjian, H. M., Giles, F. J., Gattermann, N., Bhalla, K. N., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F. E., O’Brien, S. G., Litzow, M. R., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 748

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571

Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G. E., Lin, H., Arlinghaus, R. B., & Talpaz, M. (2002) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 677

Active transport of imatinib into and out of cells: implications for drug resistance

Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004) · Blood · doi:10.1182/blood-2003-12-4276 · Cited by 657

Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia

Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 651

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Larson, R. A., Druker, B. J., Guilhot, F., O’Brien, S. G., Rivière, G., Krahnke, T., Gathmann, I., & Wang, Y. (2008) · Blood · doi:10.1182/blood-2007-10-116475 · Cited by 644

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

O’Hare, T., Eide, C. A., & Deininger, M. W. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 634

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Picard, S., Titier, K., Étienne, G., Teilhet, E., Ducint, D., Bernard, M., Lassalle, R., Marit, G., Reiffers, J. J., Bégaud, B., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036012 · Cited by 622

Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL

Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 611

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G. N., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 608

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T. T. F., Goldberg, S. L., Cervantes, F., Niederwieser, D. W., et al. (2006) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 603

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Rousselot, P. H., Huguet, F., Réa, D., Legros, L., Cayuela, J., Maarek, O., Blanchet, O., Marit, G., Gluckman, É., Reiffers, J. J., et al. (2006) · Blood · doi:10.1182/blood-2006-03-011239 · Cited by 538

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1516 · Cited by 512

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Weisberg, E., Manley, P. W., Mestan, J., Cowan‐Jacob, S. W., Ray, A., & Griffin, J. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603170 · Cited by 497

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

Marín, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R., Clark, R. E., Apperley, J. F., Milojković, D., Bua, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6565 · Cited by 489

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification

le Coutre, P., Tassi, E., Varella‐Garcia, M., Barni, R., Mologni, L., Cabrita, G. J. M., Marchesi, E., Supino, R., & Gambacorti-Passerini, C. B. (2000) · Blood · doi:10.1182/blood.v95.5.1758.005a41_1758_1766 · Cited by 484

Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients

Peng, B., Hayes, M., Resta, D. J., Racine-Poon, A., Druker, B. J., Talpaz, M., Sawyers, C. L., Rosamilia, M., Ford, J., Lloyd, P. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.050 · Cited by 471

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Cortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D., Turkina, A., Shen, Z.-X., Pasqüini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 460

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Hanfstein, B., Müller, M. C., Hehlmann, R., Erben, P., Lauseker, M., Fabarius, A. C., Schnittger, S., Haferlach, C., Göhring, G., Proetel, U., et al. (2012) · Leukemia · doi:10.1038/leu.2012.85 · Cited by 415

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., PAQUETTE, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 411

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci‐Bresler, A., Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 400

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C. B., & Boschelli, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8853 · Cited by 398

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Talpaz, M., Bekele, N. B., O'Brien, S. M., Zhou, X., Luthra, R., Garcia‐Manero, G., Giles, F. J., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404318 · Cited by 391

In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells

Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella‐Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1199 · Cited by 382

ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., Giannini, B., Trabacchi, E., Castagnetti, F., Testoni, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.531 · Cited by 377

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

Guilhot, F., Apperley, J. F., Kim, D., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., Souza, C. A. D., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 365

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Hochhaus, A., Baccarani, M., Deininger, M. W., Apperley, J. F., Lipton, J. H., Goldberg, S. L., Corm, S., Shah, N. P., Cervantes, F., Silver, R. T., et al. (2008) · Leukemia · doi:10.1038/leu.2008.84 · Cited by 352

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Khoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C. B., Baccarani, M., Kim, D., Zaritskey, A. Y., Countouriotis, A., Besson, N., Leip, E. P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390120 · Cited by 322

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

Corbin, A. S., Rosée, P. G. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 314

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Willis, S. G., Lange, T., Demehri, S., Otto, S., Crossman, L. C., Niederwieser, D. W., Stoffregen, E. P., McWeeney, S. K., Kovacs, I., Park, B. S., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1036 · Cited by 301

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

Cortes, J. E., Jabbour, E. J., Kantarjian, H. M., Yin, C. C., Shan, J., O'Brien, S. M., Garcia‐Manero, G., Giles, F. J., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 294

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

le Coutre, P., Ottmann, O. G., Giles, F. J., Kim, D., Cortes, J. E., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O’Brien, S. G., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 291

Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate

Issa, J. J., Gharibyan, V., Cortes, J. E., Jelı́nek, J., Morris, G., Verstovšek, S., Talpaz, M., Garcia‐Manero, G., & Kantarjian, H. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.981 · Cited by 288

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Müller, M. C., Cortes, J. E., Kim, D., Druker, B. J., Erben, P., Pasqüini, R., Branford, S., Hughes, T. P., Radich, J. P., Ploughman, L., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214221 · Cited by 287

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice

Hu, Y., Swerdlow, S., Duffy, T. M., Weinmann, R. S., Lee, F. Y., & Li, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606509103 · Cited by 274

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia

Milojković, D., & Apperley, J. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 271

Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia

Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer Control · doi:10.1177/107327480901600204 · Cited by 251

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Kimura, S. H., Naito, H., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara, E., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2209 · Cited by 244

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

Cortes, J. E., Talpaz, M., Giles, F. J., O'Brien, S. M., Rios, M. B., Shan, J., Garcia‐Manero, G., Faderl, S. H., Thomas, D. A., Wierda, W., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2790 · Cited by 236

Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

Lahaye, T., Riehm, B., Berger, U., Paschka, P., Müller, M. C., Kreil, S., Merx, K., Schwindel, U., Schoch, C., Hehlmann, R., et al. (2005) · Cancer · doi:10.1002/cncr.20922 · Cited by 231

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.

Gambacorti-Passerini, C. B., Zucchetti, M., Russo, D., Frapolli, R., Verga, M., Bungaro, S., Tornaghi, L., Rossi, F., Pioltelli, P. E., Pogliani, E., et al. (2003) · PubMed · Cited by 226

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

Kantarjian, H. M., Pasqüini, R., Lévy, V., Jootar, S., Hołowiecki, J., Hamerschlak, N., Hughes, T. P., Bleickardt, E. W., Dejardin, D., Cortes, J. E., et al. (2009) · Cancer · doi:10.1002/cncr.24504 · Cited by 216

hOCT 1 and resistance to imatinib

Crossman, L. C., Druker, B. J., & Deininger, M. W. (2005) · Blood · doi:10.1182/blood-2005-02-0694 · Cited by 212

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

Chu, S., Xu, H., Shah, N. P., Snyder, D., Forman, S. J., Sawyers, C. L., & Bhatia, R. (2004) · Blood · doi:10.1182/blood-2004-03-1114 · Cited by 209

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

Griswold, I. J., MacPartlin, M., Bumm, T. G. P., Goss, V. L., O’Hare, T., Lee, K. A., Corbin, A. S., Stoffregen, E. P., Smith, C., Johnson, K. J., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02202-05 · Cited by 202

Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia

Barnes, D., Palaiologou, D., Panousopoulou, E., Schultheis, B. S., Yong, A. S. M., Wong, A., Pattacini, L., Goldman, J. M., & Melo, J. V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0076 · Cited by 200

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Branford, S., Melo, J. V., & Hughes, T. P. (2009) · Blood · doi:10.1182/blood-2009-08-215939 · Cited by 197

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

White, D. L., Dang, P., Engler, J. R., Frede, A., Zrim, S., Osborn, M. P., Saunders, V. A., Manley, P. W., & Hughes, T. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5819 · Cited by 185

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Soverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Paolini, S., Rondoni, M., Piccaluga, P. P., Palandri, F., et al. (2007) · Haematologica · doi:10.3324/haematol.10822 · Cited by 184

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

Kim, D., Sriharsha, L., Xu, W., Kamel‐Reid, S., Liu, X., Siminovitch, K., Messner, H. A., & Lipton, J. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0145 · Cited by 184

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

Danhauser-riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., & Hallek, M. J. (1996) · PubMed · Cited by 182

Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression

Khorashad, J. S., de Lavallade, H., Apperley, J. F., Milojković, D., Reid, A. G., Bua, M., Szydlo, R., Olavarría, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9953 · Cited by 180

Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia

Burchert, A., Müller, M. C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., Hehlmann, R., Neubauer, A., & Hochhaus, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5075 · Cited by 177

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Abruzzese, E., Paolini, S., Merante, S., Orlandi, E. M., Matteis, S. D., Gozzini, A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-197186 · Cited by 174

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571

Corbin, A. S., Buchdunger, E., Furet, P., & Druker, B. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111525200 · Cited by 165

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

Bixby, D. L., & Talpaz, M. (2010) · Leukemia · doi:10.1038/leu.2010.238 · Cited by 163

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Shan, J., O'Brien, S. M., Reddy, N., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Verstovšek, S., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154344 · Cited by 155

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Kantarjian, H. M., Cortes, J. E., Kim, D., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E. P., Kelly, V. M., et al. (2013) · Blood · doi:10.1182/blood-2013-07-513937 · Cited by 151

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

O'Dwyer, M. E., Mauro, M. J., Kurilik, G., Mori, M., Balleisen, S., Olson, S. B., Magenis, E., Capdeville, R., & Druker, B. J. (2002) · Blood · doi:10.1182/blood-2002-03-0777 · Cited by 145

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Kantaijian, H. (2007) · Blood · Cited by 143

Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

Oki, Y., Kantarjian, H. M., Gharibyan, V., Jones, D. M., O'Brien, S. M., Verstovšek, S., Cortes, J. E., Morris, G. M., Garcia‐Manero, G., & Issa, J. J. (2007) · Cancer · doi:10.1002/cncr.22470 · Cited by 137

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Cortes, J. E., Lipton, J. H., Réa, D., Digumarti, R., Chuah, C. T. H., Nanda, N., Benichou, A., Craig, A. R., Michallet, M., Nicolini, F. E., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415307 · Cited by 134

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

Marín, D., Hedgley, C. A., Clark, R. E., Apperley, J. F., Foroni, L., Milojković, D., Pocock, C., Goldman, J. M., & O’Brien, S. J. (2012) · Blood · doi:10.1182/blood-2012-01-407486 · Cited by 130

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

Wendel, H., de Stanchina, E., Cepero, E., Ray, S., Emig, M., Fridman, J. S., Veach, D. R., Bornmann, W. G., Clarkson, B. D., McCombie, W. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602402103 · Cited by 127

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Kantarjian, H. M., Larson, R. A., Guilhot, F., O’Brien, S. G., Mone, M. D., Rudoltz, M. S., Krahnke, T., Cortes, J. E., Druker, B. J., & for the International Randomized Study of Interferon and STI571 (IRIS) Investigators (2009) · Cancer · doi:10.1002/cncr.24066 · Cited by 114

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

Wu, J. Y., Meng, F., Lu, H. Y., Kong, L. Y., Bornmann, W. G., Peng, Z., Talpaz, M., & Donato, N. J. (2008) · Blood · doi:10.1182/blood-2007-08-109330 · Cited by 112

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24601 · Cited by 109

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

Ernst, T., Erben, P., Muller, M. C., Paschka, P., Schenk, T., Hoffmann, J., Kreil, S., Rosée, P. G. L., Hehlmann, R., & Hochhaus, A. (2008) · Haematologica · doi:10.3324/haematol.11993 · Cited by 108

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase

Alvarado, Y., Kantarjian, H. M., O'Brien, S. M., Faderl, S. H., Borthakur, G. M., Burger, J. A., Wierda, W. G., Garcia‐Manero, G., Shan, J., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24418 · Cited by 106

The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.

Zonder, J. A., Pemberton, P., Brandt, H., Mohamed, A. N., & Schiffer, C. A. (2003) · PubMed · Cited by 100

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

José‐Eneriz, E. S., Agirre, X., Jiménez‐Velasco, A., Cordeu, L., Martín, V., Arqueros, V., Gárate, L., Fresquet, V., Cervantes, F., Martinez-Climent, J. A., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.005 · Cited by 91

Characterization of cancer stem cells in chronic myeloid leukaemia

Jørgensen, H. G., & Holyoake, T. L. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351347 · Cited by 91

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro

Ferrao, P. T., Frost, M. J., Siah, S.-P., & Ashman, L. K. (2003) · Blood · doi:10.1182/blood-2003-01-0083 · Cited by 88

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

Schoch, C., Haferlach, T., Kern, W., Schnittger, S., Berger, U., Hehlmann, R., Hiddemann, W., & Hochhaus, A. (2003) · Leukemia · doi:10.1038/sj.leu.2402813 · Cited by 88

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

Tipping, A. J., Mahon, F., Zafirides, G., Lagarde, V., Goldman, J. M., & Melo, J. (2002) · Leukemia · doi:10.1038/sj.leu.2402775 · Cited by 88

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

Khorashad, J. S., Milojković, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A. G., Melo, V. D., Babb, A., de Lavallade, H., Olavarría, E., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096396 · Cited by 87

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Sherbenou, D. W., Hantschel, O. D., Kaupe, I., Willis, S. G., Bumm, T. G. P., Turaga, L., Lange, T., Dao, K.-H. T., Press, R. D., Druker, B. J., et al. (2010) · Blood · doi:10.1182/blood-2008-10-183665 · Cited by 86

Resistance to Imatinib: Mutations and Beyond

Rosée, P. G. L., & Deininger, M. W. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.06.005 · Cited by 86

α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571

Jørgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., & Smith, K. D. (2002) · Blood · doi:10.1182/blood.v99.2.713 · Cited by 85

Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

Jones, D. M., Kamel‐Reid, S., Bahler, D. W., Dong, H. Y., Elenitoba‐Johnson, K. S. J., Press, R. D., Quigley, N. B., Rothberg, P. G., Sabath, D., Viswanatha, D. S., et al. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080095 · Cited by 81

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

Allan, E. K., Holyoake, T. L., Craig, A. R., & Jørgensen, H. G. (2011) · Leukemia · doi:10.1038/leu.2011.55 · Cited by 80

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib

Sherbenou, D. W., Wong, M. J., Humayun, A., McGreevey, L. S., Harrell, P. M., Yang, R., Mauro, M. J., Heinrich, M. C., Press, R. D., Druker, B. J., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404554 · Cited by 79

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Shan, J., Quintás‐Cardama, A., Garcia‐Manero, G., Rios, M. B., & Cortes, J. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0693 · Cited by 78

Omacetaxine as an Anticancer Therapeutic: What is Old is New Again

Wetzler, M., & Segal, D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049778 · Cited by 76

Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors

Lee, S. M., Bae, J. H., Kim, M. J., Lee, H. S., Lee, M. K., Chung, B., Kim, D. W., Kang, C., & Kim, S. H. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124461 · Cited by 73

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

Tang, C., Schafranek, L., Watkins, D. B., Parker, W. T., Moore, S., Prime, J. A., White, D. L., & Hughes, T. P. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.591013 · Cited by 61

The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.

Wang, L., Knight, K., Lucas, C., & Clark, R. E. (2006) · PubMed · Cited by 61

BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation

Alikian, M., Gerrard, G., Subramanian, P. G., Mudge, K., Foskett, P., Khorashad, J. S., Lim, A. C., Marín, D., Milojković, D., Reid, A. G., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22272 · Cited by 58

Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance

Kantarjian, H. M., Coutre, P. D. L., Cortes, J. E., Pinilla-Ibarz, J. A., Nagler, A., Hochhaus, A., Kimura, S. H., & Ottmann, O. G. (2010) · Cancer · doi:10.1002/cncr.25079 · Cited by 57

Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice

Branford, S. (2007) · Hematology · doi:10.1182/asheducation-2007.1.376 · Cited by 56

Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression

Ernst, T., & Hochhaus, A. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.002 · Cited by 56

Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia

Laneuville, P., DiLea, C., Yin, O. Q. P., Woodman, R. C., Mestan, J., & Manley, P. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4945 · Cited by 54

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Cortes, J. E., Kim, D., Pinilla-Ibarz, J. A., le Coutre, P., Paquette, R. L., Chuah, C. T. H., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2012) · Blood · doi:10.1182/blood.v120.21.163.163 · Cited by 54

PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

PAQUETTE, R. L., Shah, N. P., Sawyers, C. L., Martinelli, G., Nicoll, J. M., Chalukya, M., Rocchetti, M., Fiocchi, C., Comis, S., Capolongo, L., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1030.1030 · Cited by 53

Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor

Gontarewicz, A., & Brümmendorf, T. H. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_14 · Cited by 50

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Cortes, J. E., PAQUETTE, R. L., Talpaz, M., Pinilla, J., Asatiani, E., Wetzler, M., Lipton, J. H., Kasap, C., Bui, L. A., Clary, D. O., et al. (2008) · Blood · doi:10.1182/blood.v112.11.3232.3232 · Cited by 50

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

Galimberti, S., Cervetti, G., Guerrini, F., Testi, R., Pacini, S., Fazzi, R., Simi, P., & Petrini, M. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.01.015 · Cited by 49

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J. A., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G. N., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1129.1129 · Cited by 49

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

O'Brien, S. M., Berman, E., Moore, J. O., Pinilla-Ibarz, J. A., Radich, J. P., Shami, P. J., Smith, B. D., Snyder, D., Sundar, H. M., Talpaz, M., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0125 · Cited by 47

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia

Kim, T. D., Türkmen, S., Schwarz, M., Koca, G., Nogai, H., Bommer, C., Dörken, B., Daniel, P., & le Coutre, P. (2009) · Haematologica · doi:10.3324/haematol.2009.014712 · Cited by 45

Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

Cortes, J. E., Dombret, H., Schafhausen, P., Brümmendorf, T. H., Boissel, N., Latini, F., Capolongo, L., Laffranchi, B. L., & Comis, S. (2009) · Blood · doi:10.1182/blood.v114.22.864.864 · Cited by 43

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

Soverini, S., Martinelli, G., Colarossi, S., Gnani, A., Rondoni, M., Castagnetti, F., Paolini, S., Rosti, G., & Baccarani, M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70078-5 · Cited by 42

Homoharringtonine for the treatment of chronic myelogenous leukemia

Quintás‐Cardama, A., & Cortes, J. E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.6.1029 · Cited by 40

Diagnosis and management of chronic myeloid leukemia

Kantarjian, H. M., Cortes, J. E., Guilhot, F., Hochhaus, A., Baccarani, M., & Lokey, L. (2007) · Cancer · doi:10.1002/cncr.22523 · Cited by 39

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Cortes, J. E., Khoury, H. J., Nicolini, F. E., Corm, S., Lipton, J. H., Jones, D. M., Hochhaus, A., Craig, A. R., Benichou, A., Humphriss, E., et al. (2009) · Blood · doi:10.1182/blood.v114.22.644.644 · Cited by 39

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

Ernst, T., Gruber, F., Pelz-Ackermann, O., Maier, J., Pfirrmann, M., Müller, M. C., Mikkola, I., Porkka, K., Niederwieser, D. W., Hochhaus, A., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.006981 · Cited by 37

Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review

Vaidya, S., Ghosh, K., & Vundinti, B. R. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01689.x · Cited by 36

Monitoring Response and Resistance to Treatment in Chronic Myeloid Leukemia

Assouline, S. E., & Lipton, J. H. (2011) · Current Oncology · doi:10.3747/co.v18i2.391 · Cited by 35

Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia

Foran, J. M., Ravandi, F., O'Brien, S. M., Borthakur, G. M., Rios, M. B., Boone, P. A., Worrell, J., Mallett, K., Squires, M. S., Fazal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2518 · Cited by 35

Stem cell and kinase activity‐independent pathway in resistance of leukaemia to BCR‐ABL kinase inhibitors

Li, S., & Li, D. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00108.x · Cited by 34

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Saglio, G. N., Kantarjian, H. M., Shah, N. P., Jabbour, E. J., Quintás‐Cardama, A., Steegmann, J. L., Boqué, C., Chuah, C. T. H., Pavlovsky, C., Mayer, J., et al. (2012) · Blood · doi:10.1182/blood.v120.21.1675.1675 · Cited by 34

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

Hochhaus, A., Hughes, T. P., Saglio, G. N., Guilhot, F., Al‐Ali, H. K., Rosti, G., Nakaseko, C., Souza, C. A. D., Kemp, C. N., Fan, X., et al. (2012) · Blood · doi:10.1182/blood.v120.21.167.167 · Cited by 33

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

Cortes, J. E., Roboz, G. J., Kantarjian, H. M., Feldman, E. J., Karp, J. E., Pratz, K. W., Rao, N. S., Akinaga, S., & Levis, M. J. (2008) · Blood · doi:10.1182/blood.v112.11.2967.2967 · Cited by 32

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Cortes, J. E., Raghunadharao, D., Parikh, P. M., Wetzler, M., Lipton, J. H., Jones, D. M., Hochhaus, A., Kantarjian, H. M., Craig, A. R., Benichou, A., et al. (2009) · Blood · doi:10.1182/blood.v114.22.861.861 · Cited by 32

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

Itonaga, H., Tsushima, H., Hata, T., Matsuo, E., Imanishi, D., Imaizumi, Y., Kawaguchi, Y., Fukushima, T., Doi, Y., Mori, S., et al. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1005-1 · Cited by 27

Mutational analysis in chronic myeloid leukemia: when and what to do?

Branford, S., & Hughes, T. P. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32834399ef · Cited by 27

Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

Oyekunle, A. A., Klyuchnikov, E., Ocheni, S., Kröger, N. M., Zander, A. R., Baccarani, M., & Bacher, U. (2011) · Acta Haematologica · doi:10.1159/000323662 · Cited by 25

Can we afford to let sleeping dogs lie?

Deininger, M. W., & Holyoake, T. L. (2005) · Blood · doi:10.1182/blood-2004-12-4764 · Cited by 22

The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?

Cortes, J. E., Quintás‐Cardama, A., Jabbour, E. J., O'Brien, S. M., Verstovšek, S., Borthakur, G. M., Ravandi, F., Garcia‐Manero, G., Burton, E. M., Shan, J., et al. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.06.009 · Cited by 21

Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study

Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Gallagher, N. J., Baccarani, M., & LeCoutre, P. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.7029 · Cited by 21

Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228.

Shah, N. P., Kasap, C., PAQUETTE, R. L., Cortes, J. E., Pinilla, J., Talpaz, M., Bui, L. A., & Clary, D. O. (2007) · Blood · doi:10.1182/blood.v110.11.474.474 · Cited by 20

Chromosome 20q Deletion

Sun, J., Yin, C. C., Cui, W., Chen, S. S., Medeiros, L. J., & Lu, G. G. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpqfsc9zjnmaz6 · Cited by 19

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Terasawa, T., Dahabreh, I. J., & Trikalinos, T. A. (2010) · PLoS Currents · doi:10.1371/currents.rrn1204 · Cited by 19

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone

Nicolini, F. E., Hayette, S., Legros, L., Rousselot, P. H., Maloisel, F., Tulliez, M., Guerci‐Bresler, A., Charbonnier, A., Prébet, T., Huguet, F., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.010 · Cited by 16

BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

Gruber, F., Lundán, T., Goll, R., Silye, A., Mikkola, I., Rekvig, O. P., Knuutila, S., Remes, K., Gedde‐Dahl, T., Porkka, K., et al. (2011) · Medical Oncology · doi:10.1007/s12032-010-9781-z · Cited by 14

Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation

Cornelison, A. M., Welch, M.-A., Koller, C. A., & Jabbour, E. J. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.032 · Cited by 14

A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib

Giles, F. J., le Coutre, P., Bhalla, K. N., Rosti, G., Ossenkoppele, G. J., Alimena, G., Weitzman, A., Zheng, M., & Kantarjian, H. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7038 · Cited by 14

Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib‐resistant chronic myeloid leukaemia patient harbouring the BCR‐ABL1 T315I gatekeeper mutation

Coudé, M.-M., Luycx, O., Cariou, M., Maarek, O., Dombret, H., Cayuela, J., & Réa, D. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.09016.x · Cited by 13

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Kantarjian, H. M., Kim, D., Pinilla-Ibarz, J. A., le Coutre, P., PAQUETTE, R. L., Chuah, C. T. H., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2012) · Blood · doi:10.1182/blood.v120.21.915.915 · Cited by 12

A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.

Ayoubi, M., Kantarjian, H. M., Wierda, W. G., Ferrajoli, A., Hiteshew, J., Estrov, Z. E., & Cortes, J. E. (2009) · Blood · doi:10.1182/blood.v114.22.2193.2193 · Cited by 10

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

Marin, D., Hedgley, C. A., Clark, R. E., Apperley, J. F., Foroni, L., Milojković, D., Pocock, C., Goldman, J. M., & O’Brien, S. J. (2011) · Blood · doi:10.1182/blood.v118.21.785.785 · Cited by 8

Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).

Wetzler, M., Kantarjian, H. M., Nicolini, F. E., Lipton, J. H., Akard, L. P., Baccarani, M., Craig, A., Brown, P. D. N., & Cortes, J. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6604 · Cited by 8

Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs).

Akard, L. P., Kantarjian, H. M., Nicolini, F. E., Wetzler, M., Lipton, J. H., Baccarani, M., Craig, A., Nanda, N., Brown, P. D. N., & Cortes, J. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6596 · Cited by 8

Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).

Nicolini, F. E., Lipton, J. H., Kantarjian, H. M., Wetzler, M., Akard, L. P., Baccarani, M., Craig, A., Nanda, N., Brown, P. D. N., & Cortes, J. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6513 · Cited by 8

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Kantarjian, H. M., Larson, R. A., Guilhot, F., O’Brien, S. G., Mone, M. D., Rudoltz, M. S., Krahnke, T., Cortes, J. E., & Druker, B. J. (2010) · Cancer · doi:10.1002/cncr.25358 · Cited by 7

Molecular Monitoring of BCR-ABL Transcripts—Standardization Needed to Properly Use, and Further Investigate the Value of, a Critical Surrogate Marker for Success in Therapy of Chronic Myeloid Leukemia

Giles, F. J. (2011) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2011.07.2.138 · Cited by 5

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Cortes, J. E., Kantarjian, H. M., Kim, D., Turkina, A., Shen, Z., Khoury, H. J., Brümmendorf, T. H., Schafhausen, P., Vellenga, E., Pasqüini, R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.3779.3779 · Cited by 4

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Abruzzese, E., Merante, S., Breccia, M., Capucci, A., Specchia, G., Radaelli, F., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1934.1934 · Cited by 4

Real-Life Rates of Disease Monitoring in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.

Morra, E., Michallet, M., Steegmann, J. L., Costa, D. M., Ossenkoppele, G. J., Verhoef, G. E. G., Kühr, T., Björeman, M., Paga, C., Cohen, C., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1959.1959 · Cited by 4

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

Khoury, H. J., Gambacorti-Passerini, C. B., Kantarjian, H. M., Kim, D.-W., Marín, D., Dorlhiac‐Llacer, P. E., Zaritskey, A. Y., Navarro, J. R., Bullorsky, E. O., Assouline, S. E., et al. (2012) · Blood · doi:10.1182/blood.v120.21.3785.3785 · Cited by 4

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia.

Kim, D. H., Sriharsha, L., Xu, W., Kamel‐Reid, S., Liu, X., Siminovitch, K., Messner, H. A., & Lipton, J. H. (2007) · Blood · doi:10.1182/blood.v110.11.737.737 · Cited by 3

Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Kantarjian, H. M., Cortes, J. E., Kim, D., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E. P., Besson, N., et al. (2011) · Blood · doi:10.1182/blood.v118.21.2760.2760 · Cited by 3

Functional Characterization of ABCG2 Polymorphisms and Their Influence on Tyrosine Kinase Inhibitor Effects in Chronic Myeloid Leukemia Cells,

Skoglund, K., Moreno, S. B., Jönsson, J., & Gréen, H. (2011) · Blood · doi:10.1182/blood.v118.21.3495.3495 · Cited by 2

Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

Khoury, H. J., Cortes, J. E., Wetzler, M., Lipton, J. H., Baccarani, M., Douer, D., Craig, A., Kantarjian, H. M., & Akard, L. P. (2012) · Blood · doi:10.1182/blood.v120.21.3753.3753 · Cited by 1

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

Yu, Q., Eiring, A. M., Zabriskie, M. S., Khorashad, J. S., Anderson, D. J., Bryant, J. A., Loriaux, M., Tyner, J. W., O’Hare, T., & Deininger, M. W. (2011) · Blood · doi:10.1182/blood.v118.21.2481.2481 · Cited by 1

Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.

Kim, D., Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T. P., Radich, J. P., Lin, P., Saglio, G. N., Branford, S., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3441.3441 · Cited by 1

Drug resistance and combating drug resistance in cancer

Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,147

Taxanes in cancer treatment: Activity, chemoresistance and its overcoming

Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 406

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D. G. F., Réa, D., & le Coutre, P. (2014) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 264

Resisting Resistance: Targeted Therapies in Lung Cancer

Lin, J. J., & Shaw, A. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.010 · Cited by 241

Mechanisms of resistance to BCR–ABL kinase inhibitors

Diamond, J., & Melo, J. V. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546920 · Cited by 55

Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors

Labussière, H., Hayette, S., & Nicolini, F. E. (2007) · Current Pharmacogenomics · doi:10.2174/157016007781669231

Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia

Balabanov, S., Braig, M., & Brümmendorf, T. H. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.03.003 · Cited by 78

Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia

Marfè, G., & Stefano, C. (2014) · Current Drug Discovery Technologies · doi:10.2174/1570163811666140212111508 · Cited by 4

Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance

Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204